Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: An open-label study

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 16

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

392

HTML

2633

Figures (1-1)

168

Tables (1-2)

170

Sum=3363

Apr 28, 2007 (publication date) through Sep 20, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Rapid Communication

World J Gastroenterol. Apr 28, 2007; 13(16): 2328-2332
Published online Apr 28, 2007. doi: 10.3748/wjg.v13.i16.2328

Table 2 Clinical efficacy (ITT population)

Therapy/Response	n (%)
Response rates in all patients (n = 10):
Remission	1/10 (10)
Clinical improvement	3/10 (30)
No response¹	6/10 (60)
Response rates in severe colitis (n = 6):
Remission	0
Clinical improvement	1/6 (16.6)
No response¹	5/6 (83.3)

¹2 patients underwent colectomy.

Citation: Peyrin-Biroulet L, Laclotte C, Roblin X, Bigard MA. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: An open-label study. World J Gastroenterol 2007; 13(16): 2328-2332
URL: https://www.wjgnet.com/1007-9327/full/v13/i16/2328.htm
DOI: https://dx.doi.org/10.3748/wjg.v13.i16.2328